The Enhanced Liver Fibrosis (ELF™) Test helps improve the assessment of NAFLD/NASH and chronic liver disease patients at risk of disease progression.
Liver Fibrosis Assays
Help improve the assessment of NAFLD/NASH and chronic liver disease patients at risk of disease progression.
Adressing the rising prevalence of Non-alcoholic Fatty Liver Disease
Learn more about:
Enhanced Liver Fibrosis (ELF) Test
Assess the risk of NAFLD/NASH progression and liver-related events with a simple blood test.
Clinical Benefits of the ELF Test
Real-world Evidence and Value
Assessing fibrosis risk with a more accessible blood test can help improve clinical and financial outcomes.
Hear from the Experts
Hear from key opinion leaders about the rising prevalence of NAFLD/NASH and the need for non-invasive tests.
Medcape Video: Evolution of Diagnosis and Monitory for Liver Fibrosis
Four experts discuss how timely identification of patients at risk of progression using non-invasive diagnostic tests is crucial.
Siemens Healthineers offers a broad portfolio of infectious disease (ID) testing capabilities across diagnostic disciplines, from screening and diagnosis to genotyping, therapy and monitoring.
Secure your community with science and scale
As a market leader in diabetes testing, Siemens Healthineers offers a broad range of systems, assays, and point-of-care analyzers to help differentiate and monitor the diabetic patient.
Diabetes awareness for managing a healthier lifestyle